{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:12:17Z","timestamp":1789805537557,"version":"4.0.1"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"11","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Servier Laboratories | Institut de Recherches Servier"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,30]]},"abstract":"<jats:p>Chimeric antigen receptor (CAR)-T cell therapies have shown tremendous results against various hematologic cancers. Prior to cell infusion, a host preconditioning regimen is required to achieve lymphodepletion and improve CAR-T cell pharmacokinetic exposure, leading to greater chances of therapeutic success. To better understand and quantify the impact of the preconditioning regimen, we built a population-based mechanistic pharmacokinetic-pharmacodynamic model describing the complex interplay between lymphodepletion, host immune system, homeostatic cytokines, and pharmacokinetics of UCART19, an allogeneic product developed against CD19+ B cells. Data were collected from a phase I clinical trial in adult relapsed\/refractory B-cell acute lymphoblastic leukemia and revealed three different UCART19 temporal patterns: (i) expansion and persistence, (ii) transient expansion with subsequent rapid decline, and (iii) absence of observed expansion. On the basis of translational assumptions, the final model was able to capture this variability through the incorporation of IL-7 kinetics, which are thought to be increased owing to lymphodepletion, and through an elimination of UCART19 by host T cells, which is specific to the allogeneic context. Simulations from the final model recapitulated UCART19 expansion rates in the clinical trial, confirmed the need for alemtuzumab to observe UCART19 expansion (along with fludarabine cyclophosphamide), quantified the importance of allogeneic elimination, and suggested a high impact of multipotent memory T-cell subpopulations on UCART19 expansion and persistence. In addition to supporting the role of host cytokines and lymphocytes in CAR-T cell therapy, such a model could help optimizing the preconditioning regimens in future clinical trials.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>A mathematical mechanistic pharmacokinetic\/pharmacodynamic model supports and captures quantitatively the beneficial impact of lymphodepleting patients before the infusion of an allogeneic CAR-T cell product. Mediation through IL-7 increase and host T lymphocytes decrease is underlined, and the model can be further used to optimize CAR-T cell therapies lymphodepletion regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0176","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T10:48:06Z","timestamp":1667818086000},"page":"1532-1544","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2132-5173","authenticated-orcid":true,"given":"Thibaud","family":"Derippe","sequence":"first","affiliation":[{"name":"1Institut de Recherches Internationales Servier, Suresnes, France."},{"name":"2Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York."},{"name":"3Universit\u00e9 de Paris, Inserm, UMRS-1144, Optimisation Th\u00e9rapeutique en Neuropsychopharmacologie, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5898-3677","authenticated-orcid":true,"given":"Sylvain","family":"Fouliard","sequence":"additional","affiliation":[{"name":"1Institut de Recherches Internationales Servier, Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibtissam","family":"Marchiq","sequence":"additional","affiliation":[{"name":"1Institut de Recherches Internationales Servier, Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3236-2095","authenticated-orcid":true,"given":"Sandra","family":"Dupouy","sequence":"additional","affiliation":[{"name":"1Institut de Recherches Internationales Servier, Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-0919","authenticated-orcid":true,"given":"Maria","family":"Almena-Carrasco","sequence":"additional","affiliation":[{"name":"1Institut de Recherches Internationales Servier, Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Geronimi","sequence":"additional","affiliation":[{"name":"1Institut de Recherches Internationales Servier, Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9526-2294","authenticated-orcid":true,"given":"Xavier","family":"Decl\u00e8ves","sequence":"additional","affiliation":[{"name":"3Universit\u00e9 de Paris, Inserm, UMRS-1144, Optimisation Th\u00e9rapeutique en Neuropsychopharmacologie, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marylore","family":"Chenel","sequence":"additional","affiliation":[{"name":"1Institut de Recherches Internationales Servier, Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald E.","family":"Mager","sequence":"additional","affiliation":[{"name":"2Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"2023032314004324900_","first-page":"29","article-title":"Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications","volume":"8","author":"Mohseni","year":"2018","journal-title":"Am J Blood Res"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jcyt.2016.07.003","article-title":"Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells","volume":"18","author":"Geyer","year":"2016","journal-title":"Cytotherapy"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14712598.2021.1889510","article-title":"Brexucabtagene autoleucel for the treatment of relapsed\/refractory mantle cell lymphoma","volume":"21","author":"Mian","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/hum.2017.254","article-title":"CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications","volume":"29","author":"K\u00f6hl","year":"2018","journal-title":"Hum Gene Ther"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11095-018-2436-z","article-title":"Chimeric antigen receptor T-cells (CAR T-cells) for cancer immunotherapy - moving target for industry?","volume":"35","author":"Salmikangas","year":"2018","journal-title":"Pharm Res"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: more than ease of access?","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","article-title":"CAR-T efficacy: is conditioning the key?","volume":"133","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","article-title":"Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects","volume":"10","author":"Zhou","year":"2019","journal-title":"Protein Cell"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1182\/blood.V126.23.4426.4426","article-title":"Cyclophosphamide and fludarabine conditioning chemotherapy induces a key homeostatic cytokine profile in patients prior to CAR T cell therapy","volume":"126","author":"Bot","year":"2015","journal-title":"Blood"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s10875-011-9532-8","article-title":"Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice","volume":"31","author":"Parente-Pereira","year":"2011","journal-title":"J Clin Immunol"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1124\/jpet.118.252858","article-title":"Measurement and quantitative characterization of whole-body pharmacokinetics of exogenously administered T cells in mice","volume":"368","author":"Khot","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/psp4.12388","article-title":"Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor\u2013T cells","volume":"8","author":"Stein","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cpt.2040","article-title":"Model-based cellular kinetic analysis of chimeric antigen receptor-T cells in humans","volume":"109","author":"Liu","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/cts.12636","article-title":"Quantitative systems pharmacology model of chimeric antigen receptor T-cell therapy","volume":"12","author":"Hardiansyah","year":"2019","journal-title":"Clin Transl Sci"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"1688616","DOI":"10.1080\/19420862.2019.1688616","article-title":"Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model","volume":"12","author":"Singh","year":"2020","journal-title":"MAbs"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","unstructured":"Owens K , BozicI. Modelling CAR T-cell therapy with patient preconditioning. Cancer Biology; 2020. Available from: http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2020.06.20.162925.","DOI":"10.1101\/2020.06.20.162925"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T memory stem cells in health and disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat Med"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.smim.2016.02.001","article-title":"Role of memory T cell subsets for adoptive immunotherapy","volume":"28","author":"Busch","year":"2016","journal-title":"Semin Immunol"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2014-11-608539","article-title":"Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation","volume":"125","author":"Cieri","year":"2015","journal-title":"Blood"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/nri959","article-title":"Progressive differentiation and selection of the fittest in the immune response","volume":"2","author":"Lanzavecchia","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/2767-9764.CRC-22-0175","article-title":"Clinical pharmacology and determinants of response to UCART19, an allogeneic anti-CD19 CAR-T cell product, in adult B-cell acute lymphoblastic leukemia","volume":"2","author":"Dupouy","year":"2022","journal-title":"Cancer Research Communication"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/cei.13208","article-title":"Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis","volume":"194","author":"Li","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2125.2007.02914.x","article-title":"Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response","volume":"64","author":"Mould","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s40262-019-00782-0","article-title":"Population pharmacokinetics of alemtuzumab (Campath) in pediatric hematopoietic cell transplantation: towards individualized dosing to improve outcome","volume":"58","author":"Admiraal","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","article-title":"Model of chemotherapy-induced myelosuppression with parameter consistency across drugs","volume":"20","author":"Friberg","year":"2002","journal-title":"J Clin Oncol"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF01061691","article-title":"Comparison of four basic models of indirect pharmacodynamic responses","volume":"21","author":"Dayneka","year":"1993","journal-title":"J Pharmacokinet Biopharm"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.4049\/jimmunol.1600065","article-title":"Effect of anti-IL-15 administration on T cell and NK cell homeostasis in rhesus macaques","volume":"197","author":"DeGottardi","year":"2016","journal-title":"J Immunol"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3389\/fimmu.2017.00930","article-title":"Developmental and functional control of natural killer cells by cytokines","volume":"8","author":"Wu","year":"2017","journal-title":"Front Immunol"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.immunol.24.021605.090727","article-title":"Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis","volume":"24","author":"Ma","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2005.12.041","article-title":"Target-mediated drug disposition and dynamics","volume":"72","author":"Mager","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.smim.2007.10.004","article-title":"T cell immune reconstitution following lymphodepletion","volume":"19","author":"Williams","year":"2007","journal-title":"Semin Immunol"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum Interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1084\/jem.20141132","article-title":"Control of lymphocyte egress from lymph nodes through \u03b22-adrenergic receptors","volume":"211","author":"Nakai","year":"2014","journal-title":"J Exp Med"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1096\/fj.02-0548com","article-title":"Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells","volume":"16","author":"Graeler","year":"2002","journal-title":"FASEB J"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1615\/CritRevImmunol.2014009988","article-title":"Mechanism of activation-induced cell death of T cells and regulation of FasL expression","volume":"34","author":"Arakaki","year":"2014","journal-title":"Crit Rev Immunol"},{"key":"2023032314004324900_","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0176\/3221650\/crc-22-0176.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/11\/1532\/3285118\/crc-22-0176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/11\/1532\/3285118\/crc-22-0176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T05:34:23Z","timestamp":1701322463000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/11\/1532\/711340\/Mechanistic-Modeling-of-the-Interplay-Between-Host"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,30]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0176","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.22546478","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6551186","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546478.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6551186.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]}}}